These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10065363)

  • 1. Predicting drug interactions and pharmacokinetic variability with in vitro methods: the olanzapine experience.
    Wrighton SA; Ring BJ
    Drug Metab Rev; 1999 Feb; 31(1):15-28. PubMed ID: 10065363
    [No Abstract]   [Full Text] [Related]  

  • 2. A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism.
    Lucas RA; Gilfillan DJ; Bergstrom RF
    Eur J Clin Pharmacol; 1998 Oct; 54(8):639-43. PubMed ID: 9860152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers.
    Markowitz JS; Devane CL; Liston HL; Boulton DW; Risch SC
    Clin Pharmacol Ther; 2002 Jan; 71(1):30-8. PubMed ID: 11823755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine: an updated review of its use in the management of schizophrenia.
    Bhana N; Foster RH; Olney R; Plosker GL
    Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olanzapine 10-N-glucuronide. A tertiary N-glucuronide unique to humans.
    Kassahun K; Mattiuz E; Franklin R; Gillespie T
    Drug Metab Dispos; 1998 Sep; 26(9):848-55. PubMed ID: 9733662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A.
    Ring BJ; Binkley SN; Vandenbranden M; Wrighton SA
    Br J Clin Pharmacol; 1996 Mar; 41(3):181-6. PubMed ID: 8866916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ondansetron for tardive dyskinesia.
    Zullino DF; Eap CB; Voirol P
    Am J Psychiatry; 2001 Apr; 158(4):657-8. PubMed ID: 11282718
    [No Abstract]   [Full Text] [Related]  

  • 8. Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects.
    Sathirakul K; Chan C; Teng L; Bergstrom RF; Yeo KP; Wise SD
    Br J Clin Pharmacol; 2003 Aug; 56(2):184-7. PubMed ID: 12895191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine.
    Ring BJ; Catlow J; Lindsay TJ; Gillespie T; Roskos LK; Cerimele BJ; Swanson SP; Hamman MA; Wrighton SA
    J Pharmacol Exp Ther; 1996 Feb; 276(2):658-66. PubMed ID: 8632334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olanzapine transfer by human placenta.
    Schenker S; Yang Y; Mattiuz E; Tatum D; Lee M
    Clin Exp Pharmacol Physiol; 1999 Sep; 26(9):691-7. PubMed ID: 10499158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olanzapine. Pharmacokinetic and pharmacodynamic profile.
    Callaghan JT; Bergstrom RF; Ptak LR; Beasley CM
    Clin Pharmacokinet; 1999 Sep; 37(3):177-93. PubMed ID: 10511917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative determination of olanzapine in rat brain tissue by high-performance liquid chromatography with electrochemical detection.
    Bao J; Potts BD
    J Chromatogr B Biomed Sci Appl; 2001 Mar; 752(1):61-7. PubMed ID: 11254198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Monitoring of serum olanzapine during antipsychotic treatment].
    Linnet K; Olesen OV
    Ugeskr Laeger; 2000 Sep; 162(36):4802-5. PubMed ID: 10994377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring].
    Rao ML; Hiemke C; Grasmäder K; Baumann P;
    Fortschr Neurol Psychiatr; 2001 Nov; 69(11):510-7. PubMed ID: 11704898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olanzapine overdose: a pediatric case report.
    Kochhar S; Nwokike JN; Jankowitz B; Sholevar EH; Abed T; Baron DA
    J Child Adolesc Psychopharmacol; 2002; 12(4):351-3. PubMed ID: 12625996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Olanzapine (Zyprexa)].
    Sahebjam M; Serra E
    Presse Med; 2000 Dec; 29(38):2106-8. PubMed ID: 11147054
    [No Abstract]   [Full Text] [Related]  

  • 17. Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes.
    Hägg S; Spigset O; Lakso HA; Dahlqvist R
    Eur J Clin Pharmacol; 2001 Sep; 57(6-7):493-7. PubMed ID: 11699614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of olanzapine (LY170053) in human liver slices by liquid chromatography/tandem mass spectrometry.
    Murphy AT; Lake BG; Bernstein JR; Franklin RB; Gillespie TA
    J Mass Spectrom; 1998 Dec; 33(12):1237-45. PubMed ID: 9875525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Olanzapine: preclinical pharmacology and recent findings].
    Moore N
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Jun; 18(3):91-5. PubMed ID: 9800200
    [No Abstract]   [Full Text] [Related]  

  • 20. Valproic Acid and risperidone.
    Good CR; Petersen CA; Krecko VF
    J Am Acad Child Adolesc Psychiatry; 2003 Jan; 42(1):2. PubMed ID: 12500068
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.